The Roles of Neuroinflammation in l ‐DOPA‐Induced Dyskinesia: Dissecting the Roles of NF‐κB and TNF‐α for Novel Pharmacological Therapeutic Approaches
European Journal of Neuroscience · 2025
DOI: 10.1111/ejn.70034 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Neuroscience, 2025. Verfasst von Mohammad Yasin Zamanian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. Hauptthemen laut MEDLINE: NF-kappa B, Tumor Necrosis Factor-alpha, Levodopa, Dyskinesia, Drug-Induced. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 136 Literaturangaben.
Abstract (Originalsprache)
Levodopa‐induced dyskinesia (LID) is a common and debilitating complication of long‐term Parkinson's disease treatment. This review explores the roles of NF‐κB and TNF‐α signalling pathways in LID pathophysiology and potential therapeutic approaches targeting these mechanisms. Chronic levodopa treatment leads to aberrant neuroplasticity and neuroinflammation, involving activation of NF‐κB and increased production of pro‐inflammatory cytokines like TNF‐α. NF‐κB activation in glial cells contributes to sustained neuroinflammation and exacerbates dopaminergic neuron loss. TNF‐α levels are elevated in brain regions affected by LID and correlate with dyskinesia severity. Several compounds are involved in mitigating LID by modulating these pathways. Agmatine reduces NF‐κB activation and NMDA receptor expression while protecting dopaminergic neurons. Resveratrol and doxycycline demonstrate antidyskinetic effects by attenuating neuroinflammation and TNF‐α production. The Rho‐kinase (ROCK) inhibitor fasudil and cannabinoid receptor 2 (CB2) receptor agonists also show efficacy in reducing LID severity and neuroinflammation. Hydrogen gas inhalation decreases pro‐inflammatory cytokine levels associated with LID. These findings highlight the complex interplay between NF‐κB, TNF‐α and other neurotransmitter systems in LID pathogenesis. Targeting neuroinflammation and glial activation through these pathways represents a promising strategy for developing novel LID treatments. Further research is needed to fully elucidate the mechanisms and optimize therapeutic approaches targeting NF‐κB and TNF‐α signalling in LID.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
- Department of Pharmacology and Toxicology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Pirogov Russian National Research Medical University, Moscow, Russia.
- Medical University MGIMO-MED, Moscow, Russia.
- Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran.
ORCID-Profile: Mohammad Yasin Zamanian
Zitieren
APA
Zamanian, M. Y., Golmohammadi, M., Gardanova, Z. R., Rahimi, M., Khachatryan, L. G., & Khazaei, M. (2025). The Roles of Neuroinflammation in l ‐DOPA‐Induced Dyskinesia: Dissecting the Roles of NF‐κB and TNF‐α for Novel Pharmacological Therapeutic Approaches. European Journal of Neuroscience. https://doi.org/10.1111/ejn.70034
Vancouver
Zamanian MY, Golmohammadi M, Gardanova ZR, Rahimi M, Khachatryan LG, Khazaei M. The Roles of Neuroinflammation in l ‐DOPA‐Induced Dyskinesia: Dissecting the Roles of NF‐κB and TNF‐α for Novel Pharmacological Therapeutic Approaches. European Journal of Neuroscience. 2025. doi:10.1111/ejn.70034
BibTeX
@article{Zamanian2025,
author = {Zamanian, Mohammad Yasin and Golmohammadi, Maryam and Gardanova, Zhanna R and Rahimi, Mohammad and Khachatryan, Lusine G and Khazaei, Mojtaba},
title = {The Roles of Neuroinflammation in l ‐DOPA‐Induced Dyskinesia: Dissecting the Roles of NF‐κB and TNF‐α for Novel Pharmacological Therapeutic Approaches},
journal = {European Journal of Neuroscience},
year = {2025},
doi = {10.1111/ejn.70034}
}
EUVIMED